Related Experiment Videos
[Generics: similarities, bioequivalence but no conformity].
D Even-Adin1, J A De Muylder, J Sternon
1Hôpital Erasme, U.L.B.
Journal De Pharmacie De Belgique
|March 27, 2002
Summary
Generic drugs (GF) offer potential cost savings in pharmaceutical expenses. However, questions remain about their equivalence to originator medications, particularly regarding excipients and bioavailability, despite regulatory approval.
Area of Science:
- Pharmaceutical Sciences
- Health Economics
Context:
- Generic drugs (GF) are gaining interest in Belgium due to reference repayment policies.
- European regulations govern GF sales authorization, but concerns about therapeutic equivalence persist.
Purpose:
- To evaluate the potential budgetary savings from generic drugs.
- To examine the guarantees of therapeutic equivalence between generic and originator drugs.
- To identify potential discrepancies in generic drug conformity.
Summary:
- While generic drugs (GF) offer economic benefits, their identity to originator medications requires scrutiny beyond active ingredients and bioavailability.
- Key areas of non-conformity include excipient composition, patient information leaflets, and the robustness of bioavailability studies.
- Despite these concerns, the market development of generic drugs is an unavoidable economic trend.
Impact:
- Highlights the need for comprehensive evaluation of generic drugs to ensure patient safety and therapeutic efficacy.
- Informs healthcare policy regarding the adoption and reimbursement of generic medications.
- Underscores the economic imperative driving the growth of the generic pharmaceutical market.